Search research articles
Contact Us
Filters
Showing results (301-310 of 321) with videos related to
Page
of 33
Sort By:
Drug Development Research
|
February 7, 2023
Comparative anticonvulsant activity of the GABAkine KRM-II-81 and a deuterated analog
Xingjie Ping, Michelle J Meyer, Nicolas M Zahn, et al.
Alcoholism, Clinical and Experimental Research
|
April 17, 2016
A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models
Linda M Rorick-Kehn, Roberto Ciccocioppo, Conrad J Wong, et al.
Journal of Medicinal Chemistry
|
April 1, 2014
Discovery of a novel series of orally active nociceptin/orphanin FQ (NOP) receptor antagonists based on a dihydrospiro(piperidine-4,7'-thieno[2,3-c]pyran) scaffold
Miguel A Toledo, Concepción Pedregal, Celia Lafuente, et al.
Journal of Medicinal Chemistry
|
December 10, 2016
Synthesis and Characterization of a Novel γ-Aminobutyric Acid Type A (GABA<sub>A</sub>) Receptor Ligand That Combines Outstanding Metabolic Stability, Pharmacokinetics, and Anxiolytic Efficacy
Michael M Poe, Kashi Reddy Methuku, Guanguan Li, et al.
ACS Omega
|
August 15, 2022
Hydrochloride Salt of the GABAkine KRM-II-81
Md Yeunus Mian, Branka Divović, Dishary Sharmin, et al.
Biopharmaceutics & Drug Disposition
|
February 23, 2022
Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the α2/3-selective GABAkine KRM-II-81
Lalit K Golani, Branka Divović, Dishary Sharmin, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 6, 2023
Structural Analogs of the GABAkine KRM-II-81 Are Orally Bioavailable Anticonvulsants without Sedation
Kamal P Pandey, Branka Divović, Farjana Rashid, et al.
Neuropharmacology
|
January 10, 2016
In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu<sub>2/3</sub> receptor antagonist
Jeffrey M Witkin, Paul L Ornstein, Charles H Mitch, et al.
ACS Chemical Neuroscience
|
January 4, 2024
New Imidazodiazepine Analogue, 5-(8-Bromo-6-(pyridin-2-yl)-4<i>H</i>-benzo[<i>f</i>]imidazo[1,5-<i>a</i>][1,4]diazepin-3-yl)oxazole, Provides a Simplified Synthetic Scheme, High Oral Plasma and Brain Exposures, and Produces Antiseizure Efficacy in Mice, and Antiepileptogenic Activity in Neural Networks in Brain Slices from a Patient with Mesial Temporal Lobe Epilepsy
Dishary Sharmin, Branka Divović, Xingjie Ping, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 1, 2017
Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive <i>N</i>-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of Depression
J M Witkin, S N Mitchell, K A Wafford, et al.
Page
of 33
Search research articles
Search
Showing results (301-310 of 321) with videos related to
Sort By:
Page
of 33
Drug Development Research
|
February 7, 2023
Comparative anticonvulsant activity of the GABAkine KRM-II-81 and a deuterated analog
Xingjie Ping, Michelle J Meyer, Nicolas M Zahn, et al.
Alcoholism, Clinical and Experimental Research
|
April 17, 2016
A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models
Linda M Rorick-Kehn, Roberto Ciccocioppo, Conrad J Wong, et al.
Journal of Medicinal Chemistry
|
April 1, 2014
Discovery of a novel series of orally active nociceptin/orphanin FQ (NOP) receptor antagonists based on a dihydrospiro(piperidine-4,7'-thieno[2,3-c]pyran) scaffold
Miguel A Toledo, Concepción Pedregal, Celia Lafuente, et al.
Journal of Medicinal Chemistry
|
December 10, 2016
Synthesis and Characterization of a Novel γ-Aminobutyric Acid Type A (GABA<sub>A</sub>) Receptor Ligand That Combines Outstanding Metabolic Stability, Pharmacokinetics, and Anxiolytic Efficacy
Michael M Poe, Kashi Reddy Methuku, Guanguan Li, et al.
ACS Omega
|
August 15, 2022
Hydrochloride Salt of the GABAkine KRM-II-81
Md Yeunus Mian, Branka Divović, Dishary Sharmin, et al.
Biopharmaceutics & Drug Disposition
|
February 23, 2022
Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the α2/3-selective GABAkine KRM-II-81
Lalit K Golani, Branka Divović, Dishary Sharmin, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 6, 2023
Structural Analogs of the GABAkine KRM-II-81 Are Orally Bioavailable Anticonvulsants without Sedation
Kamal P Pandey, Branka Divović, Farjana Rashid, et al.
Neuropharmacology
|
January 10, 2016
In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu<sub>2/3</sub> receptor antagonist
Jeffrey M Witkin, Paul L Ornstein, Charles H Mitch, et al.
ACS Chemical Neuroscience
|
January 4, 2024
New Imidazodiazepine Analogue, 5-(8-Bromo-6-(pyridin-2-yl)-4<i>H</i>-benzo[<i>f</i>]imidazo[1,5-<i>a</i>][1,4]diazepin-3-yl)oxazole, Provides a Simplified Synthetic Scheme, High Oral Plasma and Brain Exposures, and Produces Antiseizure Efficacy in Mice, and Antiepileptogenic Activity in Neural Networks in Brain Slices from a Patient with Mesial Temporal Lobe Epilepsy
Dishary Sharmin, Branka Divović, Xingjie Ping, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 1, 2017
Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive <i>N</i>-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of Depression
J M Witkin, S N Mitchell, K A Wafford, et al.
Page
of 33